Michael Kalos

Michael Kalos is a graduate of the University of Minnesota Medical School, where he received his PhD from the department of Microbiology with an emphasis in Genetics. He completed postdoctoral fellowships at the Fred Hutchinson Cancer Research Center where he played an early role in the development of genetic approaches to redirect lymphocyte specificity. 
In 1997 Dr. Kalos joined Corixa Corporation, where he engaged in the pre-clinical immunological evaluation of novel cancer vaccines for prostate and lung cancer.

In 2004 Dr. Kalos was recruited to City of Hope where he established a GLP-level laboratory focused on the development of biomarker strategies to evaluate T cell immunotherapies. 

In 2008 Dr Kalos was recruited to the University of Pennsylvania School of Medicine where he established the Translational and Correlative Studies Laboratory, focused on development and implementation of an integrated biomarker infrastructure as part of the institution's T cell immunotherapy program. Data from his laboratory played an instrumental role in the clinical evaluation and development of the CTL019 program, and has led to a series of high-impact and field-leading publications.

In October 2013 Dr Kalos joined Eli Lilly and company as Chief Scientific Officer for Cancer Immunobiology. At Eli Lilly Dr. Kalos was responsible for establishing and developing a robust and product focused immunotherapy strategy and program.

In March of 2018 Dr. Kalos joined Janssen as Vice President, Immuno-oncology and Oncology Cellular Therapies, where is responsible for developing and leading an integrated Immunotherapy program focused on next-generation and transformative immune therapies.

Dr. Kalos is an internationally recognized expert in T cell immunotherapy. 

Kip Cross

Dan Ollendorf

Dr David Sourdive, PhD

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences. David Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.

John Bridgeman

Thierry Wurch

Luis Álvarez-Vallina

Luis Álvarez-Vallina attended Medical School at Oviedo University and completed a residency in Immunology at the Clínica Puerta de Hierro (Madrid). Luis earned a PhD in Immunology from the Autónoma University of Madrid and spent four years at the MRC Centre for Protein Engineering (Cambridge, UK). His work contributed to the first generation of CARs with costimulatory domains. Currently, he is Associate Professor at Aarhus University (Denmark) where he leads the Immunotherapy and Cell Engineering group. He is also heading the Cancer Immunotherapy Unit at Hospital Universitario 12 de Octubre, and Director Immunology Chair Merck- Francisco de Vitoria University (Spain). His experience includes generation of multispecific antibodies, and the development of cancer immunotherapy strategies based on the adoptive transfer of genetically engineered cells secreting bispecific antibodies.

Dr Zoltan Ivics

Anna Prokůpková

Dr Gemma Owens

Gemma Owens is a clinical research fellow and registrar in obstetrics and gynaecology with a specialist interest in gynaecological cancers. She attended Medical School at Queen’s University (Belfast), and completed an Academic Clinical Fellowship at St Mary’s Hospital, Manchester. She has recently completed a PhD at the University of Manchester, where she worked with Professor Robert Hawkins, Professor Richard Edmondson and Dr David Gilham. Her PhD focused on adoptive immunotherapy strategies for epithelial ovarian cancer, working on both TIL and CAR-T cell approaches. In collaboration with Oxford Biomedica, Gemma has demonstrated that 5T4 is an attractive target for CAR-T cell therapy in ovarian cancer.

Dr. Yannick Bulliard

Merethe Frosig